NCT05571293 - Combination Immunotherapy in Colorectal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

June 30, 2026

Conditions

Colorectal Neoplasms

Interventions

DRUG

Botensilimab

Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.

DRUG

Balstilimab

Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.

Trial Locations (3)

Weill Cornell Medicine/NewYork-Presbyterian Hospital, New York

Weill Cornell Medicine/New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn

Weill Cornell Medicine/NewYork Presbyterian - Queens, Flushing